Rajshi Farma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 29-12-2024
- Paid Up Capital ₹ 0.20 M
as on 29-12-2024
- Company Age 20 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -17.08%
(FY 2023)
- Profit -38.73%
(FY 2023)
- Ebitda -30.99%
(FY 2023)
- Net Worth 8.26%
(FY 2023)
- Total Assets -11.27%
(FY 2023)
About Rajshi Farma
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Shailesh Jain, Kunal Jain, and Apra Jain serve as directors at the Company.
- CIN/LLPIN
U24239DL2004PTC124755
- Company No.
124755
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Feb 2004
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Rajshi Farma Private Limited offer?
Rajshi Farma Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Digestive System API, API (Active Pharmaceutical Ingredients), Antipyretic and Analgesic API, Flavours & Aromatics, Bakery & Confectionery Flavors, Food Stabilizer, Fertilizers and Soil Additives, Potassic Fertilizers, Anti Infective Drugs & Medicines.
Who are the key members and board of directors at Rajshi Farma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kunal Jain  | Director | 21-Dec-2019 | Current |
| Shailesh Jain | Director | 20-Feb-2004 | Current |
| Apra Jain | Director | 20-Feb-2004 | Current |
Financial Performance of Rajshi Farma.
Rajshi Farma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 17.08% decrease. The company also saw a substantial fall in profitability, with a 38.73% decrease in profit. The company's net worth moved up by a moderate rise of 8.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rajshi Farma?
In 2023, Rajshi Farma had a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rajshi Farma?
Unlock and access historical data on people associated with Rajshi Farma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rajshi Farma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rajshi Farma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
